ResearcherUniversity of VeronaNo recent work listed
Massimiliano Tuveri
Matched on ORCID iD 0000-0002-0402-3993; OpenAlex author ID A5058034886. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 31
2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper
Papers 6
- The prognostic role of fatigue, depression and anxiety on postoperative outcomes after pancreatectomy for pancreatic cancer. A prospective observational study … Co-author DOI 10.1016/j.pan.2022.10.001↗
- A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy i… Co-author DOI 10.1186/s12885-021-07877-7↗
- A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
- PREPARE: PreoPerative Anxiety REduction. One-Year Feasibility RCT on a Brief Psychological Intervention for Pancreatic Cancer Patients Prior to Major Surgery. Co-author DOI 10.3389/fpsyg.2020.00362↗
- Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2019.2277↗
- Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. Co-author DOI 10.1016/j.pan.2018.04.002↗
Closest collaborators
The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Claudio Bassi · 6 shared papers, 2018–2022 · strength 0.57
- Paper The prognostic role of fatigue, depression and anxiety on postoperative outcomes after pancreatectomy for pancreatic ca… DOI 10.1016/j.pan.2022.10.001↗
- Paper PREPARE: PreoPerative Anxiety REduction. One-Year Feasibility RCT on a Brief Psychological Intervention for Pancreatic … DOI 10.3389/fpsyg.2020.00362↗
- Paper A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy… DOI 10.1186/s12885-021-07877-7↗
- Roberto Salvia · 6 shared papers, 2018–2022 · strength 0.57
- Paper The prognostic role of fatigue, depression and anxiety on postoperative outcomes after pancreatectomy for pancreatic ca… DOI 10.1016/j.pan.2022.10.001↗
- Paper PREPARE: PreoPerative Anxiety REduction. One-Year Feasibility RCT on a Brief Psychological Intervention for Pancreatic … DOI 10.3389/fpsyg.2020.00362↗
- Paper A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy… DOI 10.1186/s12885-021-07877-7↗
- Erica Secchettin · 4 shared papers, 2018–2021 · strength 0.34
- Paper PREPARE: PreoPerative Anxiety REduction. One-Year Feasibility RCT on a Brief Psychological Intervention for Pancreatic … DOI 10.3389/fpsyg.2020.00362↗
- Paper A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy… DOI 10.1186/s12885-021-07877-7↗
- Paper Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2019.2277↗
- Giuseppe Malleo · 4 shared papers, 2018–2021 · strength 0.30
- Paper A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy… DOI 10.1186/s12885-021-07877-7↗
- Paper A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pa… DOI 10.1177/1758835920947969↗
- Paper Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2019.2277↗
- Alessandro Esposito · 4 shared papers, 2018–2021 · strength 0.30
- Paper A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy… DOI 10.1186/s12885-021-07877-7↗
- Paper A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pa… DOI 10.1177/1758835920947969↗
- Paper Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2019.2277↗
- Salvatore Paiella · 4 shared papers, 2018–2021 · strength 0.30
- Paper A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy… DOI 10.1186/s12885-021-07877-7↗
- Paper A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pa… DOI 10.1177/1758835920947969↗
- Paper Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2019.2277↗
- Giovanni Marchegiani · 4 shared papers, 2018–2021 · strength 0.30
- Paper A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy… DOI 10.1186/s12885-021-07877-7↗
- Paper A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pa… DOI 10.1177/1758835920947969↗
- Paper Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2019.2277↗
- Veronica Marinelli · 2 shared papers, 2020–2022 · strength 0.27
- Paper The prognostic role of fatigue, depression and anxiety on postoperative outcomes after pancreatectomy for pancreatic ca… DOI 10.1016/j.pan.2022.10.001↗
- Paper PREPARE: PreoPerative Anxiety REduction. One-Year Feasibility RCT on a Brief Psychological Intervention for Pancreatic … DOI 10.3389/fpsyg.2020.00362↗
- Lidia Del Piccolo · 2 shared papers, 2020–2022 · strength 0.27
- Paper The prognostic role of fatigue, depression and anxiety on postoperative outcomes after pancreatectomy for pancreatic ca… DOI 10.1016/j.pan.2022.10.001↗
- Paper PREPARE: PreoPerative Anxiety REduction. One-Year Feasibility RCT on a Brief Psychological Intervention for Pancreatic … DOI 10.3389/fpsyg.2020.00362↗
- Mirko D’Onofrio · 3 shared papers, 2018–2020 · strength 0.20
- Paper A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pa… DOI 10.1177/1758835920947969↗
- Paper Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2019.2277↗
- Paper Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and propor… DOI 10.1016/j.pan.2018.04.002↗
- Davide Melisi · 3 shared papers, 2018–2020 · strength 0.20
- Paper A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pa… DOI 10.1177/1758835920947969↗
- Paper Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2019.2277↗
- Paper Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and propor… DOI 10.1016/j.pan.2018.04.002↗
- Michèle Milella · 2 shared papers, 2020–2021 · strength 0.17
- Paper A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy… DOI 10.1186/s12885-021-07877-7↗
- Paper A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pa… DOI 10.1177/1758835920947969↗
- Matteo De Pastena · 2 shared papers, 2018–2021 · strength 0.16
- Paper A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy… DOI 10.1186/s12885-021-07877-7↗
- Paper Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and propor… DOI 10.1016/j.pan.2018.04.002↗
- Giampaolo Perri · 1 shared paper, 2022 · strength 0.16
- Gabriella Lionetto Lionetto · 1 shared paper, 2022 · strength 0.16
- Francesca Simionato · 2 shared papers, 2019–2020 · strength 0.14
- Paper A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pa… DOI 10.1177/1758835920947969↗
- Paper Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2019.2277↗
- Valeria Merz · 2 shared papers, 2019–2020 · strength 0.14
- Paper A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pa… DOI 10.1177/1758835920947969↗
- Paper Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2019.2277↗
- Laura Maggino · 2 shared papers, 2018–2019 · strength 0.13
- Paper Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2019.2277↗
- Paper Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and propor… DOI 10.1016/j.pan.2018.04.002↗
- Renzo Mazzarotto · 1 shared paper, 2021 · strength 0.10
- Nicola Simoni · 1 shared paper, 2021 · strength 0.10
- Paola Capelli · 1 shared paper, 2020 · strength 0.07
- Filippo Scopelliti · 1 shared paper, 2020 · strength 0.07
- Paolo Regi · 1 shared paper, 2020 · strength 0.07
- Alessandro Giardino · 1 shared paper, 2020 · strength 0.07
- Simona Casalino · 1 shared paper, 2020 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.